ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Madduri on SWOG S0777 in Multiple Myeloma

Deepu Madduri, MD
Published: Monday, Jul 16, 2018



Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

According to results from SWOG S0777, the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (RVD) was better than the previous standard of care, lenalidomide with dexamethasone (RD). Both the overall survival and progression-free survival were improved with RVD, Madduri says.

The triplet regimen is now used at a lower dose, according to Madduri. Bortezomib is administered once weekly rather than twice a week on a 35-day cycle versus the previous 28-day cycle. Lenalidomide has also been reduced to 15 mg from the previous standard of 25 mg. 


Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

According to results from SWOG S0777, the triplet regimen bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (RVD) was better than the previous standard of care, lenalidomide with dexamethasone (RD). Both the overall survival and progression-free survival were improved with RVD, Madduri says.

The triplet regimen is now used at a lower dose, according to Madduri. Bortezomib is administered once weekly rather than twice a week on a 35-day cycle versus the previous 28-day cycle. Lenalidomide has also been reduced to 15 mg from the previous standard of 25 mg. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x